EP Patent

EP3843720A1 — Compositions of cxcr4 inhibitors and methods of preparation and use

Assigned to X4 Pharmaceuticals Inc · Expires 2021-07-07 · 5y expired

What this patent protects

The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.

USPTO Abstract

The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.

Drugs covered by this patent

Patent Metadata

Patent number
EP3843720A1
Jurisdiction
EP
Classification
—
Expires
2021-07-07
Drug substance claim
No
Drug product claim
No
Assignee
X4 Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.